The latest TNXP stock price forecast suggests potential volatility ahead, with analysts watching the $0.60 resistance level closely as biotech catalysts unfold. Trading volume has shown notable upticks, signaling increased market interest. Even though it seems like Tonix Pharmaceuticals Holding is developing its business nicely, we still like to consider how easily it could raise more money to accelerate growth. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Additionally, early clinical data for LX2020, a gene therapy for arrhythmogenic cardiomyopathy, have shown promising results, including increased PKP2 protein expression and reduced premature ventricular contractions. An interim clinical data update for LX2020 is expected in the second half of 2025. Fundamental analysis in the TNXP stock price forecast includes pipeline valuation estimates that could double market cap if regulatory milestones are achieved.
